Eton Pharmaceuticals (NASDAQ:ETON) Stock Rating Upgraded by Zacks Research

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday, Zacks reports.

Several other research analysts have also commented on the stock. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Weiss Ratings raised shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Canaccord Genuity Group lifted their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, August 14th. B. Riley Financial reiterated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Finally, HC Wainwright increased their price target on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $67.50.

Eton Pharmaceuticals Price Performance

ETON opened at $53.33 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. Eton Pharmaceuticals has a 52-week low of $14.27 and a 52-week high of $66.37. The stock has a market capitalization of $1.52 billion, a PE ratio of 140.34 and a beta of 0.90. The stock’s 50 day moving average price is $56.13 and its 200-day moving average price is $40.69.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.24. The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. On average, equities research analysts predict that Eton Pharmaceuticals will post 1.13 EPS for the current year.

Insiders Place Their Bets

In other news, insider David Krempa sold 4,166 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the sale, the insider owned 43,381 shares in the company, valued at approximately $2,388,991.67. The trade was a 8.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director directly owned 59,745 shares in the company, valued at $3,529,137.15. This represents a 45.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 79,166 shares of company stock worth $4,809,672. Company insiders own 16.49% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. EcoR1 Capital LLC increased its position in Eton Pharmaceuticals by 7.0% during the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after buying an additional 141,394 shares in the last quarter. BlackRock Inc. purchased a new position in Eton Pharmaceuticals during the second quarter valued at $68,629,000. Nantahala Capital Management LLC purchased a new position in Eton Pharmaceuticals during the second quarter valued at $42,569,426. Pillsbury Lake Capital LLC bought a new stake in Eton Pharmaceuticals in the second quarter worth $14,015,083. Finally, Panoramic Capital LLC bought a new stake in Eton Pharmaceuticals in the second quarter worth $7,537,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.